Related Experiment Video

Updated: Jun 20, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Treatment for metastatic malignant melanoma: old drugs and new strategies

Roger Mouawad1, Marie Sebert, Judith Michels

  • 1AP-HP, Salpêtrière Hospital, University of Pierre & Marie Curie Paris 6, Medical Oncology Department, 47 boulevard de l'Hôpital, Paris, France. roger.mouawad@psl.aphp.fr

Critical Reviews in Oncology/Hematology
|September 29, 2009
PubMed

Insights

Melanoma is a growing cancer with few effective treatments. This review explores current and emerging therapies for metastatic melanoma, from single agents to novel combinations.

Area of Science:

  • Oncology
  • Dermatology
  • Cancer Research

Background:

  • Melanoma incidence is rising globally, posing a significant public health challenge.
  • Metastatic melanoma is a treatment-refractory malignancy with limited therapeutic options.
  • Dacarbazine remains a common, though often insufficient, first-line treatment for metastatic melanoma.

Purpose of the Study:

  • To review established and novel therapeutic strategies for metastatic malignant melanoma.
  • To provide an overview of current chemotherapy and immunotherapy options.
  • To summarize ongoing clinical trials investigating combination therapies and new agents for melanoma.

Main Methods:

  • Literature review of clinical trials and established treatments for metastatic melanoma.
  • Analysis of single-agent therapies, including chemotherapy and immunotherapy.
  • Exploration of emerging combination therapies and novel agents in clinical development.

Main Results:

  • Chemotherapy and immunotherapy have shown limited success as single agents in metastatic melanoma.
  • Clinical trials are exploring combinations of existing treatments and novel therapeutic agents.
  • The landscape of melanoma treatment is evolving towards more targeted and combination approaches.

Conclusions:

  • There is an urgent need for more effective first-line treatments for metastatic melanoma.
  • Combination therapies and novel agents show promise in improving patient outcomes.
  • Continued research and clinical trials are crucial for advancing melanoma treatment strategies.

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...